- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07951515
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Macular Edema After Retinal Vein Occlusion (MK-8748-006)
Randomized, Double-Masked, Multicenter, 3 Arm, Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) MK-8748 Compared With Aflibercept (2 mg) in Participants With Macular Edema Following Retinal Vein Occlusion (ME-RVO)
Researchers are looking for new ways to treat macular edema after retinal vein occlusion (ME-RVO). ME-RVO happens when a vein becomes blocked in the retina, the back part of the eye. This blockage causes fluid to leak into the macula, which is the part of the retina that helps to see fine details. The buildup of fluid, called macular edema, can cause blurry vision.
In this trial, researchers want to learn if a trial medicine called MK-8748 can treat ME-RVO. A standard (usual) treatment for ME-RVO is aflibercept. However, standard treatments such as aflibercept may not work for every person.
The main goal of this trial is to learn if participants who receive MK-8748 can see as clearly as participants who receive aflibercept.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
- Phase 3
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
The main inclusion criteria include but are not limited to the following:
- Has a diagnosis of macular edema following retinal vein occlusion (ME-RVO) within 4 months (120 days) before screening and is treatment-naïve for ME-RVO
- Has a BCVA ETDRS letter score between 73 and 19 (20/40 - 20/400 Snellen equivalent), inclusive, in the study eye at screening. In the event that both eyes are eligible, the worst-seeing eye should be enrolled in the trial.
- Has a decrease in vision in the study eye determined by the investigator to be primarily the result of ME-RVO.
The main exclusion criteria include but are not limited to the following:
- Has history of stroke (cerebral vascular accident) or myocardial infarction within 180 days prior to study entry
- Has any active malignancy, except non-melanoma skin carcinoma.
- Has history of previous episodes of ME-RVO or persistent ME-RVO diagnosed more than 4 months before screening
- Has any prior steroid implant use including dexamethasone intravitreal implant (Ozurdex®) and fluocinolone acetonide intravitreal implant (Iluvien®) or other intraocular or periocular corticosteroids in the study eye at any time.
- Has prior periocular pharmacological or intravitreal treatment (including anti-vascular endothelial growth factor medication) for other retinal diseases in the study eye at any time.
- Has a history of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of screening.
- Has significant active retinal disease (ie, moderate non-proliferative diabetic retinopathy or worse, proliferative diabetic retinopathy, geographic atrophy, myopic choroidal neovascularization) other than the ME-RVO under investigation in the study eye.
- Is currently using drugs with known retinal toxicity (eg, hydroxychloroquine, pentosan polysulfate sodium).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: MK-8748 low dose
Participants receive MK-8748 low dose every 4 weeks (Q4W) administered in the study eye until week 48. After week 48, participants will be treated at intervals determined based on individualized response to treatment, up to week 96. |
Administered via intravitreal (IVT) injection
Andere Namen:
|
|
Experimental: MK-8748 High Dose
Participants receive MK-8748 high dose every 4 weeks (Q4W) administered in the study eye until week 48. After week 48, participants will be treated at intervals determined based on individualized response to treatment, up to week 96. |
Administered via intravitreal (IVT) injection
Andere Namen:
|
|
Aktiver Komparator: Aflibercept 2 mg
Participants receive aflibercept 2 mg every 4 weeks (Q4W) administered in the study eye until week 48. After week 48, participants will be treated at intervals determined based on individualized response to treatment, up to week 96. |
Administered via IVT injection
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Mean Change in Best-Corrected Visual Acuity (BCVA) (Early Treatment of Diabetic Retinopathy Study [ETDRS] Letters) From Baseline to Week 24
Zeitfenster: Baseline and Week 24
|
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. Mean change in ETDRS letters from baseline to week 24 will be assessed. |
Baseline and Week 24
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Mean Change in Central Subfield Thickness (CST) from Baseline to Week 24
Zeitfenster: Baseline and Week 24
|
Central subfield thickness (CST) in the study eye will be measured in microns using optical coherence tomography (OCT). The mean change in CST from baseline to week 24 will be presented. |
Baseline and Week 24
|
|
Mean Change in CST from Baseline Over Time
Zeitfenster: Up to approximately 96 weeks
|
Central subfield thickness (CST) in the study eye will be measured in microns using optical coherence tomography (OCT). The mean change in CST from baseline over time will be presented. |
Up to approximately 96 weeks
|
|
Time to Absence of Diabetic Macular Edema (DME)
Zeitfenster: Up to approximately 96 weeks
|
The absence of Diabetic Macular Edema (DME) is defined as a Central Subfield Thickness (CST) of <300 μm measured using optical coherence tomography (OCT). The time to absence of Diabetic Macular Edema (DME) in the study eye will be presented. |
Up to approximately 96 weeks
|
|
Proportion of Participants with Absence of Intraretinal Fluid Over Time
Zeitfenster: Up to approximately 96 weeks
|
Participants' intraretinal fluid in the study eye will be measured using optical coherence tomography (OCT). The proportion of participants with absence of intraretinal fluid over time will be presented. |
Up to approximately 96 weeks
|
|
Proportion of Participants with Absence of Subretinal Fluid Over Time
Zeitfenster: Up to approximately 96 weeks
|
Participants' subretinal fluid in the study eye will be measured using optical coherence tomography (OCT). The proportion of participants with absence of subretinal fluid over time will be presented. |
Up to approximately 96 weeks
|
|
Proportion of Participants with Absence of Intraretinal Fluid and Subretinal Fluid Over Time
Zeitfenster: Up to approximately 96 weeks
|
Participants' subretinal fluid and intraretinal fluid in the study eye will be measured using optical coherence tomography (OCT). The proportion of participants with absence of intraretinal and subretinal fluid over time will be presented. |
Up to approximately 96 weeks
|
|
Proportion of Participants with Resolution of Macular Leakage on Fluorescein Angiography (FA) at Week 24
Zeitfenster: Week 24
|
Fluorescein Angiography (FA) images will be used to determine the resolution of macular leakage in the study eye, defined as 0 to 1 mm^2. The proportion of participants with resolution of macular leakage at Week 24 will be presented. |
Week 24
|
|
Proportion of Participants with Resolution of Macular Leakage on FA at Week 48
Zeitfenster: Week 48
|
FA images will be used to determine the resolution of macular leakage in the study eye, defined as 0 to 1 mm^2. The proportion of participants with resolution of macular leakage at Week 48 will be presented. |
Week 48
|
|
Proportion of Participants with Resolution of Macular Leakage on FA at Week 96
Zeitfenster: Week 96
|
FA images will be used to determine the resolution of macular leakage in the study eye, defined as 0 to 1 mm^2. The proportion of participants with resolution of macular leakage at Week 96 will be presented. |
Week 96
|
|
Mean Change in Vascular Leakage Area on FA in the Macula From Baseline Over Time
Zeitfenster: Up to approximately 96 weeks
|
Vascular leakage area in the macula will be evaluated using FA images graded by a centralized reading center. The total area of macular vascular leakage will be measured in square millimeters (mm²). The mean change in vascular leakage area from baseline over time will be presented. |
Up to approximately 96 weeks
|
|
Mean Change From Baseline in Macular Ischemic Nonperfusion Area as Assessed by Optical Coherence Tomography Angiography (OCT-A)
Zeitfenster: Up to approximately 96 weeks
|
Macular ischemic nonperfusion area (defined as areas of capillary nonperfusion or capillary drop-out within the superficial and/or deep retinal capillary plexuses) is measured in square millimeters (mm²) using OCT-A. Images are analyzed and graded by a centralized, masked independent reading center. The mean change in ischemic nonperfusion area from baseline over time will be presented. |
Up to approximately 96 weeks
|
|
Proportion of Participants Requiring Panretinal Photocoagulation
Zeitfenster: Up to approximately 96 weeks
|
The proportion of participants requiring panretinal photocoagulation treatment will be presented. |
Up to approximately 96 weeks
|
|
Mean Number of Intravitreal (IVT) Injections from Week 48 to Week 96
Zeitfenster: Up to approximately 48 weeks
|
The mean number of intravitreal (IVT) Injections from week 48 to week 96 will be presented. |
Up to approximately 48 weeks
|
|
Proportion of Participants on a Personalized Treatment Interval (PTI) of Every 4 Weeks (Q4W) at Week 96
Zeitfenster: Up to approximately 96 weeks
|
The proportion of participants on a personalized treatment interval (PTI) of Q4W at Week 96 will be presented. |
Up to approximately 96 weeks
|
|
Proportion of Participants on a Personalized Treatment Interval (PTI) of Every 8 Weeks (Q8W) at Week 96
Zeitfenster: Up to approximately 96 weeks
|
The proportion of participants on a personalized treatment interval (PTI) of Q8W at Week 96 will be presented. |
Up to approximately 96 weeks
|
|
Proportion of Participants on a Personalized Treatment Interval (PTI) of Every 12 Weeks (Q12W) at Week 96
Zeitfenster: Up to approximately 96 weeks
|
The proportion of participants on a personalized treatment interval (PTI) of Q12W at Week 96 will be presented. |
Up to approximately 96 weeks
|
|
Proportion of Participants on a Personalized Treatment Interval (PTI) of Every 16 Weeks (Q8W) at Week 96
Zeitfenster: Up to approximately 96 weeks
|
The proportion of participants on a personalized treatment interval (PTI) of Q16W at Week 96 will be presented. |
Up to approximately 96 weeks
|
|
Mean Change in BCVA (ETDRS letters) from Baseline Over Time
Zeitfenster: Baseline and 96 weeks
|
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The mean change in BCVA (ETDRS) letters from baseline over time will be presented. |
Baseline and 96 weeks
|
|
Proportion of Participants who Gain ≥5 ETDRS Letters from Baseline at Week 24
Zeitfenster: Baseline and week 24
|
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥5 ETDRS letters from baseline to year 1 will be presented. |
Baseline and week 24
|
|
Proportion of Participants who Gain ≥10 ETDRS Letters from Baseline at Week 24
Zeitfenster: Baseline and week 24
|
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥10 ETDRS letters from baseline to year 1 will be presented. |
Baseline and week 24
|
|
Proportion of Participants who Gain ≥15 ETDRS Letters from Baseline at Week 24
Zeitfenster: Baseline and week 24
|
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥15 ETDRS letters from baseline to year 1 will be presented. |
Baseline and week 24
|
|
Proportion of Participants who Gain ≥5 ETDRS Letters from Baseline Over Time
Zeitfenster: Up to approximately 96 weeks
|
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥5 ETDRS letters from baseline over time will be presented. |
Up to approximately 96 weeks
|
|
Proportion of Participants who Gain ≥10 ETDRS Letters from Baseline Over Time
Zeitfenster: Up to approximately 96 weeks
|
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥10 ETDRS letters from baseline over time will be presented. |
Up to approximately 96 weeks
|
|
Proportion of Participants who Gain ≥15 ETDRS Letters from Baseline Over Time
Zeitfenster: Up to approximately 96 weeks
|
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥15 ETDRS letters from baseline over time will be presented. |
Up to approximately 96 weeks
|
|
Proportion of Participants who Lose ≥5 ETDRS Letters from Baseline at Week 24
Zeitfenster: Baseline and Week 24
|
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥5 ETDRS letters from baseline to week 24 will be presented. |
Baseline and Week 24
|
|
Proportion of Participants who Lose ≥10 ETDRS Letters from Baseline at Week 24
Zeitfenster: Baseline and Week 24
|
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥10 ETDRS letters from baseline to week 24 will be presented. |
Baseline and Week 24
|
|
Proportion of Participants who Lose ≥15 ETDRS Letters from Baseline at Week 24
Zeitfenster: Baseline and Week 24
|
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥15 ETDRS letters from baseline to week 24 will be presented. |
Baseline and Week 24
|
|
Proportion of Participants who Lose ≥5 ETDRS Letters from Baseline Over Time
Zeitfenster: Up to approximately 96 weeks
|
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥5 ETDRS letters from baseline over time will be presented. |
Up to approximately 96 weeks
|
|
Proportion of Participants who Lose ≥10 ETDRS Letters from Baseline Over Time
Zeitfenster: Up to approximately 96 weeks
|
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥10 ETDRS letters from baseline over time will be presented. |
Up to approximately 96 weeks
|
|
Proportion of Participants who Lose ≥15 ETDRS Letters from Baseline Over Time
Zeitfenster: Up to approximately 96 weeks
|
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥15 ETDRS letters from baseline over time will be presented. |
Up to approximately 96 weeks
|
|
Proportion of Participants with BCVA Snellen Equivalent of 20/20 or Better at Week 24
Zeitfenster: Week 24
|
Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The Snellen equivalent of 20/20 or better is defined as ≥84 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/20 or better at week 24 will be presented. |
Week 24
|
|
Proportion of Participants with BCVA Snellen Equivalent of 20/20 or Better Over Time
Zeitfenster: Up to approximately 96 weeks
|
Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The Snellen equivalent of 20/20 or better is defined as ≥84 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/20 or better over time will be presented. |
Up to approximately 96 weeks
|
|
Proportion of Participants with BCVA Snellen Equivalent of 20/40 or Better at Week 24
Zeitfenster: Week 24
|
Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The Snellen equivalent of 20/40 or better is defined as ≥70 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/40 or better at week 24 will be presented. |
Week 24
|
|
Proportion of Participants with BCVA Snellen Equivalent of 20/40 or Better Over Time
Zeitfenster: Up to approximately 96 weeks
|
Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The Snellen equivalent of 20/40 or better is defined as ≥70 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/40 or better over time will be presented. |
Up to approximately 96 weeks
|
|
Proportion of Participants with BCVA Snellen Equivalent of 20/200 or Worse at Week 24
Zeitfenster: Week 24
|
Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The Snellen equivalent of 20/200 or worse is defined as ≤38 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/200 or worse at week 24 will be presented. |
Week 24
|
|
Proportion of Participants with BCVA Snellen Equivalent of 20/200 or Worse Over Time
Zeitfenster: Up to approximately 96 weeks
|
Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The Snellen equivalent of 20/200 or worse is defined as ≤38 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/200 or worse over time will be presented. |
Up to approximately 96 weeks
|
|
Change in National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Version Composite Score Over Time
Zeitfenster: Up to approximately 96 weeks
|
The NEI-VFQ-25 is a validated and reliable 25-item survey that measures the influence of visual disability and visual symptoms on generic health domains (emotional well-being, social functioning and task-oriented domains). The composite score ranges from 0-100 with the higher score indicating better visual function. The change in NEI-VFQ-25 version composite score over time will be presented. |
Up to approximately 96 weeks
|
|
Number of Participants who Experience a Systemic Adverse Event (AE)
Zeitfenster: Up to approximately 96 weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience a systemic AE will be presented. |
Up to approximately 96 weeks
|
|
Number of Participants who Experience an Ocular Adverse Event (AE)
Zeitfenster: Up to approximately 96 weeks
|
An ocular adverse event (OAE) is defined as any untoward medical occurrence involving the eye or ocular adnexa (including eyelids, conjunctiva, lacrimal apparatus, extraocular muscles, and orbit) that: Occurs or worsens after the first administration of the investigational product (IP) or a study-related ocular procedure, and does not necessarily have a causal relationship with the IP or procedure. OAEs include, but are not limited to, changes in: Symptoms (e.g., ocular pain, photophobia, floaters, blurred vision), Visual function (e.g., best-corrected visual acuity [BCVA], visual field). Intraocular pressure (IOP), Anterior segment findings (e.g., conjunctival hyperemia, keratitis, anterior chamber inflammation), Posterior segment findings (e.g., vitreous inflammation, retinal hemorrhages, retinal tears or detachment, macular edema), or ocular adnexa (e.g., eyelid edema, ptosis). The number of participants who experience an ocular AE will be presented. |
Up to approximately 96 weeks
|
|
Number of Participants who Discontinue Study Treatment Due to an AE
Zeitfenster: Up to approximately 96 weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported. |
Up to approximately 96 weeks
|
|
Number of Participants with Antidrug Antibodies (ADA) to MK-8748
Zeitfenster: At designated time points (up to approximately 96 weeks)
|
Blood samples collected at designated timepoints will be used to determine the ADA response to MK-8748. The number of participants with ADA to MK-8748 will be presented. |
At designated time points (up to approximately 96 weeks)
|
|
Maximum Plasma Concentration (Cmax) of MK-8748
Zeitfenster: At designated time points (up to approximately 96 weeks)
|
Cmax is defined as the peak concentration over the dosing interval. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Cmax of MK-8748. |
At designated time points (up to approximately 96 weeks)
|
|
Plasma Trough Concentration (Ctrough) of MK-8748
Zeitfenster: At designated time points (up to approximately 96 weeks)
|
Ctrough is defined as the trough concentration. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Ctrough of MK-8748. |
At designated time points (up to approximately 96 weeks)
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Medical Director, Merck Sharp & Dohme LLC
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 8748-006
- U1111-1342-5647 (Registrierungskennung: UTN)
- 2026-527378-35-00 (Registrierungskennung: EU CT)
- MK-8748-006 (Andere Kennung: MSD)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .